Weekly Quick Hits (BioHealth Capital Region) – Week of May 29, 2023

Published on :

Weekly Quick Hits (BioHealth Capital Region) – Week of May 29, 2023 By Sarah EllinwoodJune 2, 2023 Funding, Awards and Collaborations BCWorld Healthcare and ReGelTec Enter Exclusive Distribution Agreement for [….]

Weekly Quick Hits (BioHealth Capital Region) – Week of May 15, 2023

Published on :

Weekly Quick Hits (BioHealth Capital Region) – Week of May 15, 2023 By Alex Keown and Sarah EllinwoodMay 19, 2023 Funding, Awards and Collaborations PQE Group US Earns 2023 Great [….]

Sirnaomics Marks 15th Anniversary with Opening of New US Headquarters and Laboratories in Germantown, Maryland

Published on :

Sirnaomics Ltd. (Stock Code: 2257 HK) and its affiliates and subsidiaries (collectively, “Sirnaomics”), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, celebrated Sirnaomics’ 15th anniversary of RNAi therapeutic innovation globally, along with the grand opening of the new headquarters and laboratories for its US subsidiary in Germantown, Maryland, on Dec. 15, 2022.

Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

Published on :

Sirnaomics Ltd. (the “Company” or “Sirnaomics”, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the cohort receiving the 180μg dose level in the Phase II clinical trial of STP705 for the treatment of cutaneous basal cell carcinoma (BCC) achieved a 100% complete response (CR), indicating the promising viability of the treatment. STP705 is a siRNA (small interfering RNA) therapeutic that is composed of two siRNA oligonucleotides, targeting the expression of TGF-β1 and COX-2 mRNA, respectively.

Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ English

Published on :

Sirnaomics Ltd. (the “Company” or “Sirnaomics”, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Company has dosed the first patient in a Phase I/II clinical study of STP705, the Company’s leading siRNA (small interfering RNA) drug candidate, for the treatment of patients with facial squamous cell skin cancer in situ (isSCC).

Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology

Published on :

Sirnaomics Ltd. (“Sirnaomics”, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the peer-reviewed publication of Phase IIa clinical study results of its lead therapeutic candidate, STP705, for the treatment of skin cancer, in the May 2022 issue of the Journal of Drugs in Dermatology (the “JDD”). The study, titled “Safety and Efficacy of TGF-β1/COX-2 Silencing Therapeutic in Adults with Cutaneous Squamous Cell Carcinoma In Situ,” showed that STP705 was safe and well-tolerated in patients with Cutaneous Squamous Cell Carcinoma In Situ (isSCC).

Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment

Published on :

Sirnaomics Ltd. (the “Company” or “Sirnaomics”, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the launch of a Phase I clinical trial of the Company’s siRNA (small interfering RNA) drug candidate, STP705, in adults undergoing abdominoplasty for submental fat reduction. This study is the first application for Sirnaomics to apply an RNAi therapeutic candidate for medical cosmetology treatment.

End of Year Update: 2020 Life Science Venture Capital Funding Roundup in the BioHealth Capital Region

Published on :

This has certainly been a year unlike any other for BioHealth Capital Region (BHCR) life science companies of all sizes and kinds. Just a few months into 2020, the coronavirus pandemic swept the region, seriously disrupting, albeit temporarily, the best laid plans of aspiring founders, entrepreneurs, emerging startups, pre-clinical and more established, larger biohealth organizations in Virginia, Washington, D.C. and Maryland.

21 Emerging Life Science Companies Fueling Maryland’s Biohealth Ecosystem

Published on :

Maryland is the epicenter of biotech and life science innovation in the BioHealth Capital Region (BHCR). The state is home to a burgeoning life science ecosystem, including a rapidly growing cell and gene therapy industry, a robust and growing advanced biomanufacturing environment, and a deep network of leading research universities and critical government life science research entities.